Association between acute pancreatitis and COVID-19 infection: What do we know?

被引:6
|
作者
Jablonska, Beata [1 ]
Olakowski, Marek [1 ]
Mrowiec, Slawomir [1 ]
机构
[1] Med Univ Silesia, Dept Digest Tract Surg, Medykow 14, PL-40752 Katowice, Poland
来源
关键词
SARS-CoV-2; COVID-19; Acute pancreatitis; Angiotensin-converting enzyme 2; PATIENT;
D O I
10.4240/wjgs.v13.i6.548
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also called coronavirus disease 2019 (COVID-19), first originated in Wuhan, China, displaying atypical pneumonia-like respiratory symptoms in affected patients. SARS-CoV-2 primarily attacks the respiratory system, and the most common symptoms include cough, shortness of breath, and fever. However, its impact on the digestive system has been shown, and various clinical gastrointestinal manifestations of this disease have been recognized. Some reports have shown acute pancreatitis (AP) as the initial symptom in patients with COVID-19. AP may be a consequence of direct pancreatic damage by the virus because pancreatic acinar cells contain angiotensin-converting enzyme 2 receptor proteins, and SARS-CoV-2 can bind to these receptors, causing pancreatic injury. Moreover, AP may be a secondary indicator of cytokine storms and altered inflammatory responses. Our review of the literature shows that SARS-CoV-2 appears to be a new etiological infectious factor related to AP. In this manuscript, a comprehensive review of case reports and case series of patients with AP and COVID-19 is presented. All reports on COVID-19-associated AP are summarized. All cases are thoroughly analyzed and discussed in-depth.
引用
收藏
页码:548 / 562
页数:15
相关论文
共 50 条
  • [41] COVID-19 and the liver: What do we know so far?
    Prashant Nasa
    George Alexander
    [J]. World Journal of Hepatology, 2021, 13 (05) : 522 - 532
  • [42] Elective procedures in times of COVID-19: ?What do we know?
    Ensuncho, Cesar
    [J]. ARCHIVOS DE MEDICINA, 2020, 20 (02): : 513 - 517
  • [43] COVID-19 and diabetes: What do we know so far?
    Gangadaran, Prakash
    Padinjarathil, Himabindu
    Rajendran, Shri Hari Subhashri
    Jogalekar, Manasi P.
    Hong, Chae Moon
    Aruchamy, Baladhandapani
    Rajendran, Uma Maheswari
    Gurunagarajan, Sridharan
    Krishnan, Anand
    Ramani, Prasanna
    Subramanian, Kavimani
    [J]. EXPERIMENTAL BIOLOGY AND MEDICINE, 2022, 247 (15) : 1330 - 1334
  • [44] COVID-19 and the liver: What do we know so far?
    Nasa, Prashant
    Alexander, George
    [J]. WORLD JOURNAL OF HEPATOLOGY, 2021, 13 (05) : 522 - 532
  • [45] COVID-19 and Myocarditis: What Do We Know So Far?
    Pirzada, Ashar
    Mokhtar, Ahmed T.
    Moeller, Andrew D.
    [J]. CJC OPEN, 2020, 2 (04) : 278 - 285
  • [46] COVID-19 vaccines: what do we know so far?
    Dhillon, Paraminder
    Altmann, Daniel
    Male, Victoria
    [J]. FEBS JOURNAL, 2021, 288 (17) : 4996 - 5009
  • [47] Breast Milk and COVID-19: What Do We Know? COMMENT
    Kimberlin, David W.
    Puopolo, Karen M.
    [J]. CLINICAL INFECTIOUS DISEASES, 2021, 72 (01) : 131 - 132
  • [48] COVID-19 and the gastrointestinal tract: what do we already know?
    Machado de Almeida, Joana Ferro
    Chehter, Ethel Zimberg
    [J]. EINSTEIN-SAO PAULO, 2020, 18 : eRW5909
  • [49] What do we know about Kawasaki disease and COVID-19?
    Alberto Hernandez Arias, Jeffrey James William
    Herrera de la Hoz, Rosa Elena
    Lequerica Segrera, Pedro Luis
    [J]. ANDES PEDIATRICA, 2021, 92 (02): : 281 - 287
  • [50] COVID-19 and Anemia: What Do We Know So Far?
    Abu-Ismail, Luai
    Taha, Mohammad J. J.
    Abuawwad, Mohammad T.
    Al-Bustanji, Yaqeen
    Al-Shami, Khayry
    Nashwan, Abdulqadir
    Yassin, Mohamed
    [J]. HEMOGLOBIN, 2023, 47 (03) : 122 - 129